Tirzepatide is the first dual-target therapy that activates both GIP and GLP-1 receptors, helping manage blood sugar levels ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Mounjaro in India rose 60% in May from April, the first full month the popular weight loss/diabetes drug was available in the ...

The manufacturer of Mounjaro has responded to dangerous hack that’s been doing the rounds on social media. Videos of people ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Previous clinical studies suggested that - when combined with changes to their diet, exercise and behavioural support - ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...